{
  "case_id": "Case_11",
  "model_id": "deepseek/deepseek-r1",
  "content": "{\n    \"primary_diagnosis\": {\n        \"name\": \"G6PD deficiency with drug-induced hemolytic anemia\",\n        \"confidence\": 0.85,\n        \"icd_code\": \"D55.0\",\n        \"reasoning\": \"Middle Eastern ethnicity increases risk for G6PD deficiency. Semaglutide is not a classic trigger, but new medications in G6PD-deficient patients can unmask susceptibility. Presentation with jaundice, dark urine (bilirubinuria), fatigue, and splenomegaly suggests acute hemolysis.\"\n    },\n    \"differential_diagnoses\": [\n        {\n            \"name\": \"Autoimmune hemolytic anemia\",\n            \"confidence\": 0.4,\n            \"icd_code\": \"D59.1\",\n            \"reasoning\": \"Acute onset anemia with jaundice and splenomegaly could indicate immune-mediated destruction. Requires Coombs test to confirm.\"\n        },\n        {\n            \"name\": \"Semaglutide-induced hepatotoxicity\",\n            \"confidence\": 0.25,\n            \"icd_code\": \"K71.9\",\n            \"reasoning\": \"Rare reports of Wegovy causing transaminase elevations. Less likely given dark urine suggests hemolysis rather than pure hepatocellular injury.\"\n        },\n        {\n            \"name\": \"Thalassemia intermedia/crisis\",\n            \"confidence\": 0.3,\n            \"icd_code\": \"D56.3\",\n            \"reasoning\": \"Regional prevalence in Middle East and splenomegaly. However, acute onset after medication initiation favors hemolytic trigger over chronic hemoglobinopathy.\"\n        }\n    ],\n    \"key_findings\": [\n        \"Jaundice with scleral icterus\",\n        \"Dark urine (suggestive of hemoglobinuria/bilirubinuria)\",\n        \"Tachycardia and pallor (signs of anemia)\",\n        \"Recent semaglutide initiation\"\n    ],\n    \"diagnostic_tests\": [\n        {\n            \"test\": \"G6PD enzyme assay\",\n            \"purpose\": \"Confirm G6PD deficiency\",\n            \"priority\": \"immediate\"\n        },\n        {\n            \"test\": \"Peripheral blood smear\",\n            \"purpose\": \"Assess for hemolytic changes (bite cells, Heinz bodies)\",\n            \"priority\": \"immediate\"\n        },\n        {\n            \"test\": \"Reticulocyte count\",\n            \"purpose\": \"Evaluate bone marrow response to anemia\",\n            \"priority\": \"urgent\"\n        },\n        {\n            \"test\": \"Direct antiglobulin test (Coombs)\",\n            \"purpose\": \"Rule out autoimmune hemolysis\",\n            \"priority\": \"urgent\"\n        }\n    ],\n    \"management_plan\": {\n        \"immediate_actions\": [\n            \"Discontinue semaglutide immediately\",\n            \"Hydration with IV fluids\"\n        ],\n        \"medications\": [\n            {\n                \"drug\": \"Folic acid\",\n                \"dose\": \"1 mg daily\",\n                \"route\": \"PO\",\n                \"duration\": \"30 days\",\n                \"rationale\": \"Support increased RBC production in hemolysis\"\n            }\n        ],\n        \"monitoring\": [\n            \"Hemoglobin/HCT every 6-8 hours\",\n            \"Urine output hourly\",\n            \"Serial bilirubin levels\"\n        ],\n        \"consultations\": [\n            {\n                \"specialty\": \"Hematology\",\n                \"urgency\": \"immediate\",\n                \"reason\": \"Confirm hemolytic etiology and guide management\"\n            }\n        ]\n    },\n    \"red_flags\": [\n        \"Hemoglobin <7 g/dL requiring transfusion\",\n        \"Development of oliguria or renal injury\",\n        \"Neurological changes suggesting bilirubin encephalopathy\"\n    ],\n    \"patient_education\": [\n        \"Avoid future oxidative stressors (specific medications, fava beans)\",\n        \"Carry G6PD deficiency alert if confirmed\",\n        \"Report dark urine or jaundice immediately with new medications\"\n    ],\n    \"follow_up\": {\n        \"timing\": \"24-48 hours for lab trend reassessment\",\n        \"conditions\": \"Worsening fatigue, chest pain, or decreased urine output\"\n    },\n    \"confidence_in_assessment\": 0.8,\n    \"uncertainties\": [\n        \"Exact trigger medication (possible undisclosed concomitant agents)\",\n        \"Baseline G6PD status unknown\",\n        \"Possibility of concurrent liver pathology\"\n    ]\n}",
  "latency": 52.51686072349548,
  "timestamp": "2025-08-10T01:29:12.025452",
  "cached_at": "2025-08-10T01:29:12.025458"
}